134 related articles for article (PubMed ID: 8215712)
1. Presence of immunoreactive platelet-activating factor in peritoneal exudate induced by zymosan in rats.
Damas J; Prunescu P
Arch Int Pharmacodyn Ther; 1993; 322():115-23. PubMed ID: 8215712
[TBL] [Abstract][Full Text] [Related]
2. Inhibition by WEB 2086, a PAG-acether antagonist of oedema and peritonitis induced by zymosan in rats.
Damas J; Remacle-Volon G; Nguyen TP
Arch Int Pharmacodyn Ther; 1990; 306():161-9. PubMed ID: 2076045
[TBL] [Abstract][Full Text] [Related]
3. Production of platelet-activating factor in inflammatory exudate.
Oh-ishi S; Imai Y; Hayashi M
J Lipid Mediat; 1992; 5(2):115-20. PubMed ID: 1525350
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages.
Zhang F; Decker K
Eur Cytokine Netw; 1994; 5(3):311-7. PubMed ID: 7948767
[TBL] [Abstract][Full Text] [Related]
5. Involvement of platelet-activating factor in zymosan-induced rat pleurisy.
Imai Y; Hayashi M; Oh-ishi S
Lipids; 1991 Dec; 26(12):1408-11. PubMed ID: 1819742
[TBL] [Abstract][Full Text] [Related]
6. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
Floch A; Tahraoui L; Sedivy P; Cavero I
J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
[TBL] [Abstract][Full Text] [Related]
7. Involvement of platelet-activating factor in the hypotensive response to zymosan in rats.
Damas J
J Lipid Mediat; 1991; 3(3):333-44. PubMed ID: 1773031
[TBL] [Abstract][Full Text] [Related]
8. Absence of a lyso-PAF relationship with PAF (platelet activating factor) in monosodium urate crystal-induced inflammatory exudates.
Griswold DE; Hillegass L; Rotilio D; Mong S; Hanna N
Eicosanoids; 1989; 2(3):151-6. PubMed ID: 2629894
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS.
Pires AL; e Silva PM; Pasquale C; Castro-Faria-Neto HC; Bozza PT; Cordeiro RS; Rae GA; Braquet P; Lagente V; Martins MA
Br J Pharmacol; 1994 Nov; 113(3):994-1000. PubMed ID: 7858896
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antagonist activity of the PAF antagonists RP 59227 and WEB 2086 on elicited guinea pig peritoneal macrophages. Evidence for variable affinities and kinetics.
Turner NC; Wood LJ
J Pharmacol Exp Ther; 1992 Sep; 262(3):1139-46. PubMed ID: 1326625
[TBL] [Abstract][Full Text] [Related]
14. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
Issekutz AC; Szpejda M
Lab Invest; 1986 Mar; 54(3):275-81. PubMed ID: 3951199
[TBL] [Abstract][Full Text] [Related]
15. Platelet-activating factor and the vascular effects of zymosan in rats.
Damas J; Remacle-Volon G; Bourdon V
Eur J Pharmacol; 1993 Feb; 231(2):231-6. PubMed ID: 8453979
[TBL] [Abstract][Full Text] [Related]
16. Resident peritoneal leukocytes are important sources of MMP-9 during zymosan peritonitis: superior contribution of macrophages over mast cells.
Kolaczkowska E; Lelito M; Kozakiewicz E; van Rooijen N; Plytycz B; Arnold B
Immunol Lett; 2007 Nov; 113(2):99-106. PubMed ID: 17826846
[TBL] [Abstract][Full Text] [Related]
17. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological modulation of Paf-induced rat pleurisy and its role in inflammation by zymosan.
Martins MA; Silva PM; Faria Neto HC; Bozza PT; Dias PM; Lima MC; Cordeiro RS; Vargaftig BB
Br J Pharmacol; 1989 Feb; 96(2):363-71. PubMed ID: 2924083
[TBL] [Abstract][Full Text] [Related]
19. Key role of complement activation and platelet-activating factor in exudate formation in zymosan-induced rat pleurisy.
Imai Y; Hayashi M; Oh-ishi S
Jpn J Pharmacol; 1991 Oct; 57(2):225-32. PubMed ID: 1812301
[TBL] [Abstract][Full Text] [Related]
20. Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes.
Chávez-Cartaya RE; Metcalfe S; Ramirez-Romero P; Calne R; Jamieson NV
Transplantation; 1994 May; 57(10):1440-4. PubMed ID: 8197604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
